These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3130072)

  • 1. Novel 1-haloalkyl-2-nitroimidazole bioreductive alkylating agents.
    Heimbrook DC; Shyam K; Sartorelli AC
    Anticancer Drug Des; 1988 Mar; 2(4):339-50. PubMed ID: 3130072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents.
    Teicher BA; Sartorelli AC
    J Med Chem; 1980 Aug; 23(8):955-60. PubMed ID: 7190617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV; Bloomer WD
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
    Kirkpatrick DL; Johnson KE; Sartorelli AC
    J Med Chem; 1986 Oct; 29(10):2048-52. PubMed ID: 3761323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
    Keyes SR; Fracasso PM; Heimbrook DC; Rockwell S; Sligar SG; Sartorelli AC
    Cancer Res; 1984 Dec; 44(12 Pt 1):5638-43. PubMed ID: 6437671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
    Lin TS; Teicher BA; Sartorelli AC
    J Med Chem; 1980 Nov; 23(11):1237-42. PubMed ID: 7452674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-electron reduction of mitomycin c by rat liver: role of cytochrome P-450 and NADPH-cytochrome P-450 reductase.
    Vromans RM; van de Straat R; Groeneveld M; Vermeulen NP
    Xenobiotica; 1990 Sep; 20(9):967-78. PubMed ID: 2122607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
    Moselen JW; Hay MP; Denny WA; Wilson WR
    Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mitomycin C by NADPH:cytochrome P-450 reductase.
    Bligh HF; Bartoszek A; Robson CN; Hickson ID; Kasper CB; Beggs JD; Wolf CR
    Cancer Res; 1990 Dec; 50(24):7789-92. PubMed ID: 2123741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia.
    Melo T; Ballinger JR; Rauth AM
    Biochem Pharmacol; 2000 Sep; 60(5):625-34. PubMed ID: 10927020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2- and 6-methyl-1,4-naphthoquinone derivatives and potential bioreductive alkylating agents.
    Antonini I; Lin TS; Cosby LA; Dai YR; Sartorelli AC
    J Med Chem; 1982 Jun; 25(6):730-5. PubMed ID: 7097727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR; Rockwell S; Sartorelli AC
    Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine.
    Langenbacher M; Abdel-Jalil RJ; Voelter W; Weinmann M; Huber SM
    Strahlenther Onkol; 2013 Mar; 189(3):246-54. PubMed ID: 23361139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage.
    O'Neill P; Jenkins TC; Stratford IJ; Silver AR; Ahmed I; McNeil SS; Fielden EM; Adams GE
    Anticancer Drug Des; 1987 Apr; 1(4):271-80. PubMed ID: 3450299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerobic and hypoxic toxicity of a new class of mixed-function drugs associating nitroimidazoles and chloroethylnitrosourea in nitrosourea-sensitive (Mer-) and -resistant (Mer+) human tumor cells.
    Mulcahy RT; Carminati A; Barascut JL; Imbach JL
    Cancer Res; 1988 Feb; 48(4):798-801. PubMed ID: 3338077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reduction.
    Moody CJ; O'Sullivan N; Stratford IJ; Stephens MA; Workman P; Bailey SM; Lewis A
    Anticancer Drugs; 1994 Jun; 5(3):367-72. PubMed ID: 7919462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
    Kennedy KA; Rockwell S; Sartorelli AC
    Cancer Res; 1980 Jul; 40(7):2356-60. PubMed ID: 7388797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.